Charlene McEvoy, MD, MPH

  Regions Pulmonary & Critical Care Division
  Assistant Professor of Medicine, University of MN
  Investigator, HealthPartners Research Foundation
  Pulmonary Specialist and Clinic Lead Physician,
  HealthPartners Specialty Medical Center


Board Certification:  Internal Medicine, Pulmonary Medicine, Critical Care Medicine
Contact:  charlene.e.mcevoy@healthpartners.com


Research Activities

• Co-Investigator, COPD Research Network, NHLBI RFA  submitted November 13, 2002.  Collaborative effort with VA Medical Center, Mayo Clinic and HealthPartners Research Foundation as a clinical trial study site for the evaluation of new and current treatments of COPD.
• Co-Investigator, AZMATICS Study, RO1 submitted to NHLBI, October 1, 2002.  Multicenter study evaluating the use of azithromycin in problematic adult asthma.
• Principal Investigator, Sleep Disturbance and Lung Disease in Older Adults; RO1 submitted to NHLBI, June 1, 2002.  Collaborative study with Hennepin County Medical Center, University of Minnesota and HealthPartners Research Foundation evaluating the impact of sleep disturbance on the course of COPD in adults 70+.
• Clinical Investigator, TENOR Study, Observational study on the epidemiology of moderate to severe asthma, Genetech sponsored, 2001.

Current Grant Support

• A07-127 – Genetic Epidemiology of Chronic Obstructive Pulmonary Disease
  Site PI (PI: James D. Crapo, MD)
  1U01HL089856nbsp;                                        Source: National Jewish Health
  Start Date: February, 2007                               Duration: 5 years

  The purpose of this study is to discover genetic factors that might predict who will devlop COPD.  Millions of Americans have this condition.  Smoking is the number one risk factor for the development of COPD, yet only a minority of smokers get COPD.  The factors that distinguish the smokers who get COPD from those who do not are not known.  Some people may develop COPD because of their genetic make-up makes them either more or less susceptible to the effects of cigarette smoke.  We will also assess genetic factors that are associated with other smoking-related disorders such as cancer or heart/vascular disease. 

• A08-012 - A 24 Week Randomized Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered By Handihaler® Once-Dailey Plus PRN Albuteral (Salbutamol) vs. Placebo Plus PRN Albuterol (Salbutomol) in Chronic Obstructive Pulmonary Disease Subjects Naïve to Maintenance Therapy (SPIRIVA)
  Role on Project: Site PI
  Source: Pfizer, Inc.                             March 2008 - February 2010 
  
  The objective of this study is to access the efficacy and safety of tiotropium in subjects with COPD (GOLD Stage II) who have not previously been treated with maintenance therapy, i.e. who have not been treated with other than only short acting agonist on an as-needed basis in the six month prior to study enrollment and who have symptomatic shortness of breath. 

  Recent Grant Support

• 2007  Spiration, Inc.
  A07-058 - Spiration IBV Valve Trial-Effectiveness of the IBV Valve System for the Treatment of Severe Emphysema
  Site PI
  July 2007 - June 2008

2006   National Heart, Lung and Blood Institute         
X0510000 - The Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbation
Co-Investigator and Site PI  (PI: Richard Albert, MD)

Selected Recent Publications 

McEvoy CE, Niewoehner DE.  Adverse effects of corticosteroid therapy for COPD.  A critical review.  Chest 1997; 111: 732-43.

McEvoy CE, Ensrud KE, Bender E, Genant HK, YU W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive lung disease. Am J Respir Crit Care Med 1998; 157: 704-709.

McEvoy CE and Niewoehner DE. Corticosteroid use in COPD: risks and benefits. Clinics in Chest Med 2000; 21(4):739-52.

McEvoy CE. Woodruff NK AIR2 Trial: bronchial thermoplasty for asthma: changing the landscape for future treatment. Advance for Managers of Respiratory Care. 2007 Oct;16(8):22-5.  

P. Shah, MD, MBBS, FRCP, J. Fiterman, MD, C. McEvoy, MD, S. Erzurum, MD. Safety of bronchial thermoplasty (BT) in patients with severe, symptomatic asthma: positive safety profile in the AIR2 trial. Am J Respir Crit Care Med. 2009; 179:A2814.